AnaptysBio Q2 Collaboration Revenue Plummets 64%
Ticker: ANAB · Form: 10-Q · Filed: Aug 6, 2025 · CIK: 1370053
| Field | Detail |
|---|---|
| Company | Anaptysbio, Inc (ANAB) |
| Form Type | 10-Q |
| Filed Date | Aug 6, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biotechnology, Pharmaceuticals, Collaboration Revenue, Q2 Earnings, SEC Filing, Drug Development, Financial Performance
Related Tickers: ANAB
TL;DR
ANAB's Q2 revenue drop is a red flag; collaboration revenue is too volatile, making it a risky bet.
AI Summary
ANAPTYSBIO, INC reported a significant decrease in collaboration revenue for the three and six months ended June 30, 2025. For the three months ended June 30, 2025, collaboration revenue was $95,000, a substantial drop from $264,000 in the same period of 2024, representing a 64% decrease. The six months ended June 30, 2025, saw collaboration revenue of $404,000, down from $365,000 in the prior year, an increase of 10.7%. The company's net income figures are not explicitly detailed in the provided snippet, but the revenue decline suggests potential pressure on profitability. Key business changes include the ongoing reliance on collaboration agreements for revenue generation. Risks are primarily associated with the variability of collaboration revenue, as evidenced by the quarter-over-quarter decline. The strategic outlook appears to involve continued development and monetization of their pharmaceutical preparations, though specific pipeline updates are not available in this excerpt. The company's financial health is heavily tied to the success and timing of these collaboration milestones.
Why It Matters
This sharp decline in Q2 collaboration revenue for ANAPTYSBIO, INC signals potential headwinds for investors, as the company heavily relies on these agreements for funding its drug development. A sustained drop could impact the company's ability to invest in its pipeline, potentially slowing down the introduction of new pharmaceutical preparations to the market. For employees, this could indicate future resource constraints or strategic shifts. In a competitive biotech landscape, consistent revenue is crucial for maintaining market position and attracting new partners, making this a critical metric for ANAB's long-term viability and competitive standing.
Risk Assessment
Risk Level: high — The risk level is high due to the significant 64% decrease in collaboration revenue for the three months ended June 30, 2025, falling to $95,000 from $264,000 in the prior year. This substantial quarter-over-quarter volatility in a primary revenue stream indicates an unpredictable financial outlook and high dependence on milestone payments from partners.
Analyst Insight
Investors should exercise caution and thoroughly investigate the reasons behind the 64% drop in Q2 collaboration revenue. Consider if this is a one-off event or indicative of a broader trend in ANAPTYSBIO's partnership agreements before making any investment decisions.
Financial Highlights
- revenue
- $95,000
- revenue Growth
- -64.0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Collaboration Revenue | $95,000 | -64.0% |
| Collaboration Revenue | $404,000 | +10.7% |
Key Numbers
- $95,000 — Q2 2025 Collaboration Revenue (Represents a 64% decrease from Q2 2024.)
- $264,000 — Q2 2024 Collaboration Revenue (Baseline for comparison, showing a significant drop in 2025.)
- 64% — Q2 Revenue Decrease (Indicates substantial volatility and risk in primary revenue stream.)
- $404,000 — H1 2025 Collaboration Revenue (Shows a 10.7% increase compared to H1 2024, contrasting with the quarterly decline.)
- $365,000 — H1 2024 Collaboration Revenue (Baseline for comparison for the six-month period.)
- 10.7% — H1 Revenue Increase (Despite the Q2 drop, the six-month period shows growth, suggesting uneven revenue recognition.)
Key Players & Entities
- ANAPTYSBIO, INC (company) — filer of the 10-Q
- $95,000 (dollar_amount) — collaboration revenue for Q2 2025
- $264,000 (dollar_amount) — collaboration revenue for Q2 2024
- 64% (dollar_amount) — percentage decrease in Q2 collaboration revenue
- $404,000 (dollar_amount) — collaboration revenue for H1 2025
- $365,000 (dollar_amount) — collaboration revenue for H1 2024
- 10.7% (dollar_amount) — percentage increase in H1 collaboration revenue
- June 30, 2025 (date) — end of the reporting period
- August 6, 2025 (date) — filing date of the 10-Q
FAQ
What was ANAPTYSBIO, INC's collaboration revenue for Q2 2025?
ANAPTYSBIO, INC reported collaboration revenue of $95,000 for the three months ended June 30, 2025.
How did ANAPTYSBIO, INC's Q2 2025 collaboration revenue compare to Q2 2024?
Collaboration revenue for Q2 2025 was $95,000, a 64% decrease from $264,000 reported in Q2 2024.
What was the collaboration revenue for ANAPTYSBIO, INC for the first six months of 2025?
For the six months ended June 30, 2025, ANAPTYSBIO, INC's collaboration revenue was $404,000.
How does ANAPTYSBIO, INC's H1 2025 collaboration revenue compare to H1 2024?
ANAPTYSBIO, INC's collaboration revenue for H1 2025 was $404,000, an increase of 10.7% from $365,000 in H1 2024.
What are the primary risks highlighted by ANAPTYSBIO, INC's Q2 2025 revenue figures?
The primary risk is the significant volatility in collaboration revenue, evidenced by the 64% quarter-over-quarter decline, indicating an unpredictable revenue stream heavily reliant on specific milestones.
What is the strategic outlook for ANAPTYSBIO, INC based on this 10-Q?
The strategic outlook appears to involve continued reliance on collaboration agreements for revenue and funding, with the success and timing of these agreements being critical for the company's financial performance.
Why is collaboration revenue important for ANAPTYSBIO, INC?
Collaboration revenue is crucial for ANAPTYSBIO, INC as it serves as a primary source of funding for its pharmaceutical preparations development and operations, directly impacting its financial health and growth prospects.
What should investors consider regarding ANAPTYSBIO, INC's Q2 2025 performance?
Investors should consider the significant 64% drop in Q2 collaboration revenue as a potential red flag, requiring further investigation into the sustainability and predictability of ANAPTYSBIO, INC's revenue streams.
When was ANAPTYSBIO, INC's 10-Q filing for Q2 2025 submitted?
ANAPTYSBIO, INC's 10-Q filing for the period ended June 30, 2025, was filed on August 6, 2025.
What industry does ANAPTYSBIO, INC operate in?
ANAPTYSBIO, INC operates in the pharmaceutical preparations industry, focusing on drug development and related collaborations.
Risk Factors
- Volatility of Collaboration Revenue [high — financial]: The company's Q2 2025 collaboration revenue of $95,000 represents a 64% decrease from $264,000 in Q2 2024. This significant quarter-over-quarter decline highlights the inherent risk and unpredictability associated with revenue streams dependent on collaboration agreements and milestone achievements.
- Reliance on Collaboration Agreements [high — financial]: AnaptysBio's financial performance is heavily tied to its collaboration agreements. The substantial drop in Q2 revenue underscores the vulnerability of this model, as fluctuations in these agreements can directly impact the company's financial health and ability to fund ongoing operations and development.
Industry Context
AnaptysBio operates in the pharmaceutical preparations sector, a highly competitive and research-intensive industry. Companies in this space often rely on strategic partnerships and collaborations to fund drug development and navigate the complex regulatory landscape. The success of such collaborations is critical for advancing pipelines and generating revenue.
Regulatory Implications
As a pharmaceutical company, AnaptysBio is subject to stringent regulatory oversight from bodies like the FDA. Changes in regulatory requirements or delays in drug approvals can significantly impact development timelines and the realization of revenue from collaboration milestones.
What Investors Should Do
- Monitor collaboration agreement updates
- Analyze revenue recognition patterns
Glossary
- Collaboration Revenue
- Revenue generated from agreements with other companies, often involving upfront payments, milestone payments, and royalties related to the development and commercialization of pharmaceutical products. (This is the primary revenue source for AnaptysBio, and its significant quarter-over-quarter decline is a key concern for investors.)
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing view of the company's financial position during the year. (This document provides the latest financial and operational updates for AnaptysBio, including the revenue figures discussed.)
Year-Over-Year Comparison
The current 10-Q filing for the period ending June 30, 2025, shows a stark 64% decrease in Q2 collaboration revenue compared to the same quarter in the prior year ($95,000 vs. $264,000). While the first six months of 2025 show a modest 10.7% increase in collaboration revenue ($404,000 vs. $365,000), the quarterly downturn introduces significant volatility. No new risks were explicitly detailed in the provided snippet, but the existing risk of revenue variability from collaborations is amplified by this quarter's performance.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding ANAPTYSBIO, INC (ANAB).